1FW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number :

10/562,625

Confirmation No.:

8272

**Applicant** 

: Gregoire Prevost

Filed

: March 1, 2006

Title

PRODUCT COMPRISING AT LEAST ONE PHOSPHATASE CDC5 INHIBITOR

COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT

TC/Art Unit

: 1624

Examiner:

: TUCKER, Zachary C

Docket No.

58767.000041

Customer No.

21967

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

In accordance with 37 C.F.R. §1.98(a)(2)(ii), copies of U.S. patents and/or U.S. patent application publications cited on the attached Form PTO-SB/08A (modified), are not being provided.

In considering the cited references enclosed with this communication, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited

Application No.: 10/562,625 Attorney Docket No. 58767.000041

references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing and the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action, or within three months of the filing date of the application. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

**HUNTON & WILLIAMS LLP** 

Dated:

JBV/mec

By:

ff/B//Vockrodt

Registration No. 54,833

Hunton & Williams LLP Intellectual Property Department 1900 K Street, N.W. Suite 1200 Washington, DC 20006 (202) 955-1500 (telephone) (202) 778-2201 (facsimile)